Erratum: Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors: The Bambino Gesù Children's Hospital experience. Cancer. 2006;106(8):1838–45.


The original article to which this Erratum refers was published in Cancer (2006) 106(8):1838–45

In the article cited above, an error has been discovered in the description of the ICE-CAV treatment on page 1839.

For the ICE-CAV regimen, doxorubicin should be utilized at a rate of 75 mg/m2 as a 72-hour continuous infusion, not 75 mg/m2 per day as a 72-hour continuous infusion.

Results and conclusions of this article remain unchanged.

The authors regret this error.